ARHGAP23: A Potential Drug Target and Biomarker for GTPase-Activating Proteins

Target Name: ARHGAP23

NCBI ID: G57636

ARHGAP23

ARHGAP23: A Potential Drug Target and Biomarker for GTPase-Activating Proteins

Introduction

GTPase-activating proteins (GAPs) are a family of transmembrane proteins that play a crucial role in intracellular signaling. They are involved in regulating various cellular processes, including cell growth, differentiation, and survival. GAPs can be classified into two distinct types: GAPs that activate GTPase and GAPs that activate GDPase. GAPs that activate GTPase are also known as GTPase-activating proteins (GAPs) or ARHGAPs. In this article, we will focus on ARHGAP23, a GAP that activates GTPase and has potential as a drug target or biomarker.

Structure and Function

ARHGAP23 is a 21-kDa protein that is expressed in various tissues, including brain, heart, and muscle. It is a member of the ARHGAP family, which includes several similar proteins that share a conserved catalytic core. The catalytic core of ARHGAP23 consists of a GAP-activating loop (GAL) and a GAP-closing loop (GCL) that are connected by a hydrogen bond. The N-terminus of ARHGAP23 contains a putative N-methylation site (NMS) that may play a role in regulating its stability and localization to the cytoplasm.

ARHGAP23 is involved in regulating various cellular processes, including cell signaling, cytoskeletal organization, and cell survival. One of its key functions is to regulate the activity of other GAPs, including the neurotransmitter-dependent K+ channels. ARHGAP23 has been shown to activate GTPase and regulate the activity of several GAPs, including ERG-1/ERG-2, a protein that is involved in the regulation of neurotransmitter release.

ARHGAP23 has also been shown to play a role in the regulation of cell survival. GAPs are often involved in the regulation of cell death, and ARHGAP23 is no exception. Research has shown that ARHGAP23 has been shown to promote the survival of cancer cells, and may be a potential biomarker for cancer.

Drug Target Potential

ARHGAP23 has several potential drug targets. One of the most promising targets is the inhibition of ARHGAP23 activity, which could lead to the inhibition of GTPase and the regulation of cellular processes. This could be achieved through various mechanisms, including inhibition of the NMS site, which is known to play a role in the regulation of protein stability and localization.

Another potential drug target for ARHGAP23 is the inhibition of its interaction with other GAPs. GAPs often interact with each other to regulate cellular processes, and ARHGAP23 may interact with other GAPs to regulate its own activity. inhibition of ARHGAP23 interaction with other GAPs could lead to the regulation of cellular processes and the inhibition of disease processes.

Biomarker Potential

ARHGAP23 has the potential to serve as a biomarker for various diseases, including cancer. Its involvement in the regulation of cellular processes and its ability to promote the survival of cancer cells make it an attractive candidate for cancer biomarker.

ARHGAP23 has also been shown to be involved in the regulation of neurotransmitter release, which is a key aspect of brain function. Its involvement in this process suggests that ARHGAP23 may be involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease.

Conclusion

In conclusion, ARHGAP23 is a GAP that activates GTPase and has

Protein Name: Rho GTPase Activating Protein 23

Functions: GTPase activator for the Rho-type GTPases by converting them to an inactive GDP-bound state

The "ARHGAP23 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARHGAP23 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets